BiotechTube
CO.DON

CO.DON

Berlin, Germany· Est.
codon.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CO.DON is a clinical-stage biotech company developing autologous cell therapies for cartilage repair, aiming to delay or avoid joint replacement surgery. The company's lead product, M-ACT (Matrix-associated Autologous Chondrocyte Transplantation), is an approved therapy in the EU. Following its 2023 acquisition by the global regenerative medicine group ReLive Biotechnology, CO.DON is positioned to expand its commercial footprint and pipeline under new leadership. The company targets the significant unmet medical need in orthopedics caused by degenerative joint diseases and sports injuries.

OrthopedicsRegenerative Medicine

Technology Platform

Autologous cell expansion and matrix-associated transplantation for cartilage repair (M-ACT platform).

Opportunities

The global acquisition by ReLive opens access to large markets like China and the US, significantly expanding the addressable patient population for its approved M-ACT therapy.
The growing, active aging population and high prevalence of joint disorders create a substantial and expanding market for joint-preserving therapies that can delay costly replacement surgery.

Risk Factors

Commercial success depends on securing favorable reimbursement and surgeon adoption in competitive EU markets and new regions.
The company faces competition from other cell-based therapies, scaffolds, and surgical techniques, requiring continuous demonstration of superior long-term outcomes and cost-effectiveness.

Competitive Landscape

CO.DON operates in the competitive orthopedic biologics and cartilage repair market, competing against other autologous cell therapy products (e.g., from Vericel), allograft-based solutions, bone marrow stimulation techniques (microfracture), and scaffold technologies. Its differentiation lies in its personalized, matrix-assisted approach and established EU approval, but it must contend with both established and emerging players.

More companies in Cell & Gene Therapy →More companies in Germany →